Page last updated: 2024-08-23

zidovudine and aplaviroc

zidovudine has been researched along with aplaviroc in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bonny, T; Clumeck, N; Currier, J; Kleim, JP; Lazzarin, A; McCarty, D; Millard, J; Slims, J; Sloan, L; Steel, H1
Amrine-Madsen, H; Demarest, JF; Irlbeck, DM; Kitrinos, KM1

Reviews

1 review(s) available for zidovudine and aplaviroc

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

2 trial(s) available for zidovudine and aplaviroc

ArticleYear
Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
    Antiviral therapy, 2008, Volume: 13, Issue:2

    Topics: Adult; Aged; Anti-HIV Agents; Benzoates; Diketopiperazines; Double-Blind Method; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Piperazines; Reverse Transcriptase Inhibitors; Spiro Compounds; Treatment Outcome; Zidovudine

2008
Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3

    Topics: Anti-HIV Agents; Benzoates; Diketopiperazines; Drug Combinations; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV-1; Humans; Lamivudine; Phylogeny; Piperazines; Receptors, CCR5; Reverse Transcriptase Inhibitors; Spiro Compounds; Treatment Failure; Tropism; Zidovudine

2009

Other Studies

1 other study(ies) available for zidovudine and aplaviroc

ArticleYear
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011